CClinicalTrials.gg
CompletedNCT07772271Distal LockingUpdated Aug 19, 2026

Dynamic Versus Static Distal Interlocking In AO/OTA 31A2 Intertrochanteric Femur Fractures: A Prospective Randomized Controlled Trial

An interventional study of Dynamic Distal Interlocking Intramedullary Nailing and Static Distal Interlocking Intramedullary Nailing in Intertrochanteric Femur Fracture, sponsored by Bozyaka Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Bozyaka Training and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

  1. INFORMATION ABOUT THE RESEARCH Title of the Research: Comparison of radiological and functional outcomes of static and dynamic locking in AO type 31A2 trochanteric fractures treated with PFN.

    Content: Investigating and comparing the effects of dynamic versus static locking on radiological and functional outcomes in AO Type 31A2 trochanteric fractures treated with Proximal Femoral Nail (PFN).

    Aim: AO type 31A2 fractures are unstable, and PFN is predominantly preferred for their surgery. There is no absolute consensus on the locking style of these nails. This study aims to comparatively evaluate the effects of static and dynamic locking on radiological and functional outcomes.

    Estimated Duration: 6 months.

    Expected Number of Volunteers: Approximately 100 patients applying within 6 months.

    Procedures and Treatment: Prospective randomization.

  2. EXPECTED BENEFIT(S) Determining which type of locking is more advantageous in AO type 31A2 fractures and contributing to the literature.
  3. RISKS AND DISCOMFORTS Both dynamic and static locking are successfully applied in AO type 31A2 fractures. There is no extra risk or discomfort for patients related to this study.
  4. MEDICAL BENEFITS FOR VOLUNTEERS The treatment applied in this study may keep your condition under control, or help diagnose your condition using the data obtained. Additionally, the results may be used for the benefit of others.
  5. PREGNANCY Pregnant individuals are excluded from the study.
  6. ALTERNATIVE TREATMENTS Patients will be randomly assigned to dynamic or static locking. I have learned that other appropriate methods exist for my condition aside from the study procedures, but they will not be used here. If I decline to participate, I retain the right to receive those alternative treatments.
  7. WITHDRAWAL FROM THE STUDY Your doctor may remove you from the study without your permission if you fail to follow the treatment requirements, disrupt the schedule, become pregnant, experience side effects, or for reasons to increase treatment efficacy.
  8. COVERAGE OF EXPENSES All examinations, physical checks, and research costs will not be charged to you or any official/private institution.
  9. FINANCIAL COMPENSATION You will not receive any payment for participating. Travel expenses will be covered if necessary.
  10. CONTACT FOR ISSUES

    For further information or any issues during the study, you can contact the doctor below:

    Dr. Fatih IŞIK \| Phone: 0-507 6961679

  11. COMPENSATION FOR DAMAGES I have been informed that if I suffer harm due to this study, necessary medical care will be provided by the researcher, and I am insured against any damage (including injury and death) arising from the study procedure, with expenses covered.
  12. VOLUNTARY PARTICIPATION AND WITHDRAWAL RIGHTS

    1. I am participating voluntarily without any pressure.
    2. I was informed of my right to refuse participation.
    3. I can withdraw at any time without giving a reason by notifying the researcher, and this will not affect my current or future medical care.
    4. The researcher or sponsor may remove me from the study without my consent due to non-compliance or to enhance my medical care quality.
  13. CONFIDENTIALITY Results may be presented in scientific meetings or publications, but my identity will be kept strictly confidential.
  14. CONSENT TO PARTICIPATE I have read or had this Informed Consent Form read to me in my native language. The contents were explained verbally and in writing. I had the opportunity to ask questions and received satisfactory answers. By signing, I voluntarily agree to participate without any pressure.

A signed copy of this form has been given to me.

02

Conditions studied

  • Intertrochanteric Femur Fracture

Keywords

  • Intertrochanteric Femur Fracture
  • AO/OTA 31A2
  • Distal Interlocking
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 65 years and older.
  • Radiographically confirmed AO/OTA 31A2 intertrochanteric femur fracture.
  • Treated with the same proximal femoral nail system.
  • Availability for postoperative clinical and radiographic follow-up.

Exclusion criteria

Exclusion Criteria:

  • Pathological fractures.
  • Polytrauma.
  • Previous surgery on the ipsilateral hip or femur.
  • Incomplete baseline radiographic data.
  • Follow-up shorter than 24 months.

    *Death before the final follow-up.

  • Incomplete final clinical or radiographic outcome data.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Dynamic Distal Interlocking Group

    Patients treated with an intramedullary nail using a dynamic distal interlocking configuration.

    Procedure: Dynamic Distal Interlocking Intramedullary Nailing

  • Active comparator
    Static Distal Interlocking Group

    Static Distal Interlocking Intramedullary Nailing'

    Procedure: Static Distal Interlocking Intramedullary Nailing

Interventions

  • ProcedureDynamic Distal Interlocking Intramedullary Nailing

    Dynamic Distal Interlocking Intramedullary Nailing'

  • ProcedureStatic Distal Interlocking Intramedullary Nailing

    Patients treated with an intramedullary nail using a static distal interlocking configuration.

05

What researchers measure

Primary outcomes

  1. Postoperative Thigh Pain

    Evaluation of the presence of localized postoperative thigh pain (ipsilateral lateral or anterolateral thigh) at final follow-up based on standardized patient interview and physical examination.

    Time frame: From date of surgery until final follow-up, assessed up to 30 months (minimum 24 months)

Secondary outcomes

  1. Harris Hip Score (HHS)

    Assessment of overall hip function using the Harris Hip Score at final follow-up.

    Time frame: From date of surgery until final follow-up, assessed at 24 months postoperatively

Other outcomes

  1. Union and Non-Union Rate

    Evaluation of fracture union (bridging callus across at least three cortices and absence of pain during weight bearing) versus non-union (absence of progressive healing by 6 months, persistent fracture line, or implant failure).

    Time frame: From date of surgery until final follow-up, assessed up to 30 months

  2. Distal Cortical Thickening

    Assessment of new or progressive focal cortical hypertrophy around the distal locking screw or nail tip on serial radiographs.

    Time frame: From date of surgery until final follow-up, assessed up to 30 month

  3. Composite Mechanical Complication Rate

    Measurement of cephalic lag screw backout, occurrence of peri-implant fractures, and the composite mechanical complication rate defined as the sum of non-union and peri-implant fracture.

    Time frame: From date of surgery until final follow-up, assessed up to 30 month

06

Study locations

1 site
  • Izmir City Hospital
    Izmir, İzmir 35170, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07772271
Lead sponsor
Bozyaka Training and Research Hospital
Responsible party
Melikşah Uzakgider (MD, Bozyaka Training and Research Hospital) — Principal investigator
First posted
Aug 19, 2026
Start date
Sep 1, 2020
Primary completion
Sep 1, 2022
Completion
Jul 1, 2026
Last update
Aug 19, 2026

Study contacts

Melikşah U Uzakgider, M.D.
study director · Izmir City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion